• Yoko Nakamura, Hidefumi Ishikawa, Katsuya Kawai, Yasuhiko Tabata, and Shigehiko Suzuki.
• Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, Japan; Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Japan. Electronic address: nyoko107@gmail.com.
• Biomaterials. 2013 Dec 1;34(37):9393-400.

AbstractThe objective of this study was to investigate the ability of mesenchymal stem cells (MSC) genetically engineered with stromal cell-derived factor-1 (SDF-1) to heal skin wounds. When transfected with SDF-1 plasmid DNA, MSC which were isolated from the bone marrow of rats, secreted SDF-1 for 7 days. In vitro cell migration assay revealed that the SDF-1-engineered MSC (SDF-MSC) enhanced the migration of MSC and dermal fibroblasts to a significantly greater extent than MSC. The SDF-MSC secreted vascular endothelial growth factor, hepatocyte growth factor, and interleukin 6 at a significantly high level. A skin defect model of rats was prepared and MSC and SDF-MSC were applied to the wound to evaluate wound healing in terms of wound size and histological examinations. The wound size decreased significantly faster with SDF-MSC treatment than with MSC and PBS treatments. The length of the neoepithelium and the number of blood vessels newly formed were significantly larger. A cell-tracing experiment with fluorescently labeled cells demonstrated that the percent survival of SDF-MSC in the tissue treated was significantly high compared with that of MSC. It was concluded that SDF-1 genetic engineering is a promising way to promote the wound healing activity of MSC for a skin defect.Copyright © 2013 Elsevier Ltd. All rights reserved.

22 keywords...

hide…